HomeCompareGILD vs TGT

GILD vs TGT: Dividend Comparison 2026

GILD yields 2.34% · TGT yields 3.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TGT wins by $4.93M in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
TGT
TGT
● Live price
3.82%
Share price
$118.75
Annual div
$4.54
5Y div CAGR
68.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.96M
Annual income
$3,876,267.92
Full TGT calculator →

Portfolio growth — GILD vs TGT

📍 TGT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDTGT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + TGT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
TGT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
TGT
Annual income on $10K today (after 15% tax)
$324.97/yr
After 10yr DRIP, annual income (after tax)
$3,294,827.73/yr
At 15% tax rate, TGT beats the other by $3,293,455.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + TGT for your $10,000?

GILD: 50%TGT: 50%
100% TGT50/50100% GILD
Portfolio after 10yr
$2.49M
Annual income
$1,938,941.41/yr
Blended yield
77.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
TGT
Analyst Ratings
27
Buy
28
Hold
4
Sell
Consensus: Hold
Price Target
$114.06
-3.9% upside vs current
Range: $81.00 — $145.00
Altman Z
3.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
TGT buys
0
No recent congressional trades found for GILD or TGT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDTGT
Forward yield2.34%3.82%
Annual dividend / share$3.19$4.54
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%68.5%
Portfolio after 10y$29.1K$4.96M
Annual income after 10y$1,614.90$3,876,267.92
Total dividends collected$7.6K$4.84M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Staples
Analyst consensusBuyHold
Analyst price target$158.71$114.06

Year-by-year: GILD vs TGT ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrTGT PortfolioTGT Income/yrGap
1← crossover$10,974$274.45$11,344$644.20$370.00TGT
2$12,073$330.19$13,289$1,150.83$1.2KTGT
3$13,316$398.20$16,342$2,123.00$3.0KTGT
4$14,730$481.49$21,598$4,111.36$6.9KTGT
5$16,345$583.87$31,666$8,556.46$15.3KTGT
6$18,199$710.26$53,638$19,755.86$35.4KTGT
7$20,340$866.96$110,091$52,698.15$89.8KTGT
8$22,826$1,062.22$288,127$170,328.82$265.3KTGT
9$25,731$1,306.80$1,010,291$701,995.64$984.6KTGT
10$29,147$1,614.90$4,957,279$3,876,267.92$4.93MTGT

GILD vs TGT: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

TGTConsumer Staples

Target Corporation operates as a general merchandise retailer in the United States. The company offers food assortments, including perishables, dry grocery, dairy, and frozen items; apparel, accessories, home décor products, electronics, toys, seasonal offerings, food, and other merchandise; and beauty and household essentials. It also provides in-store amenities, such as Target Café, Target Optical, Starbucks, and other food service offerings. The company sells its products through its stores; and digital channels, including Target.com. As of March 09, 2022, the company operated approximately 2,000 stores. Target Corporation was incorporated in 1902 and is headquartered in Minneapolis, Minnesota.

Full TGT Calculator →
📬

Get this GILD vs TGT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.